In the latest session, Adaptive Biotechnologies Corp (NASDAQ: ADPT) closed at $3.78 up 3.56% from its previous closing price of $3.65. In other words, the price has increased by $+0.1300 from its previous closing price. On the day, 1623953 shares were traded.
Ratios:
For a deeper understanding of Adaptive Biotechnologies Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.50 and its Current Ratio is at 4.66. In the meantime, Its Debt-to-Equity ratio is 0.74 whereas as Long-Term Debt/Eq ratio is at 0.71.
On January 05, 2023, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $15.
Piper Sandler Upgraded its Neutral to Overweight on December 21, 2022, whereas the target price for the stock was revised from $7.50 to $14.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 05 ’24 when ROBINS CHAD M sold 48,673 shares for $3.43 per share. The transaction valued at 167,007 led to the insider holds 2,576,701 shares of the business.
RUBINSTEIN JULIE sold 39,070 shares of ADPT for $135,764 on Mar 05 ’24. The President now owns 472,754 shares after completing the transaction at $3.47 per share. On Mar 05 ’24, another insider, BENZENO SHARON, who serves as the Chief Commercial Ofc Imm Med of the company, sold 29,390 shares for $3.44 each. As a result, the insider received 100,994 and left with 327,415 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADPT now has a Market Capitalization of 529.59M and an Enterprise Value of 281.96M. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.22 while its Price-to-Book (P/B) ratio in mrq is 1.78. Its current Enterprise Value per Revenue stands at 1.66 whereas that against EBITDA is -1.49.
Stock Price History:
Over the past 52 weeks, ADPT has reached a high of $9.08, while it has fallen to a 52-week low of $2.61. The 50-Day Moving Average of the stock is 4.1116, while the 200-Day Moving Average is calculated to be 5.4696.
Shares Statistics:
For the past three months, ADPT has traded an average of 1.49M shares per day and 1.47M over the past ten days. A total of 145.08M shares are outstanding, with a floating share count of 141.81M. Insiders hold about 2.27% of the company’s shares, while institutions hold 95.40% stake in the company. Shares short for ADPT as of Feb 15, 2024 were 9.19M with a Short Ratio of 6.18, compared to 8.76M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.35% and a Short% of Float of 8.15%.
Earnings Estimates
There are 6 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.35 for the current quarter, with a high estimate of -$0.33 and a low estimate of -$0.37, while EPS last year was -$0.4. The consensus estimate for the next quarter is -$0.33, with high estimates of -$0.31 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$1.29 and -$1.37 for the fiscal current year, implying an average EPS of -$1.31. EPS for the following year is -$1.06, with 6 analysts recommending between -$0.65 and -$1.29.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $38.21M this quarter.It ranges from a high estimate of $40M to a low estimate of $34.8M. As of the current estimate, Adaptive Biotechnologies Corp’s year-ago sales were $37.65M, an estimated increase of 1.50% from the year-ago figure.
A total of 8 analysts have provided revenue estimates for ADPT’s current fiscal year. The highest revenue estimate was $183.4M, while the lowest revenue estimate was $170M, resulting in an average revenue estimate of $175.61M. In the same quarter a year ago, actual revenue was $170.28M, up 3.10% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $220.99M in the next fiscal year. The high estimate is $256.8M and the low estimate is $195.5M. The average revenue growth estimate for next year is up 25.80% from the average revenue estimate for this year.
